🧫

Diosmin cognitive rescue in APP/PS1 mice

active
experiment Created: 2026-04-10T14:45:43 By: etl-v1-backfill Quality: 50% ✓ SciDEX ID: exp-7546a04b-9784-49f5-93c0-fa06965cddad
🧫 Experiment Protocol ValidationAlzheimer's diseaseNEPAPP/PS1 miceproposed
Behavioral study to assess the therapeutic potential of diosmin, an AhR agonist, in rescuing cognitive deficits in APP/PS1 transgenic mice. The experiment used established behavioral tests including the object recognition test and Morris water maze to evaluate learning and memory function. This study aimed to determine whether the molecular effects of AhR activation on NEP expression translate into functional cognitive improvements in an Alzheimer's disease mouse model.
PRIMARY OUTCOME
Cognitive performance
EXPECTED OUTCOMES
1. The intervention targeting NEP shifts Cognitive performance in the predicted direction relative to the matched control arm. 2. Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects. 3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.
SUCCESS CRITERIA
- Prespecified primary endpoint (Cognitive performance) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study. - The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset. - Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.
PROTOCOL
1. Establish APP/PS1 mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for NEP, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure Cognitive performance together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: Behavioral study to assess the therapeutic potential of diosmin, an AhR agonist, in rescuing cognitive deficits in APP/PS1 transgenic mice. The experiment used established behavioral tests including the object recognition test and Morris water maze to evaluate
🧫 Experiment Extras
PATHWAY
AhR-NEP-Aβ clearance pathway
MARKET PRICE
$0.50
STATUS
proposed
Metadataorigin_type: v1_polymorphic_backfill
origin_typev1_polymorphic_backfill
source_tableexperiments
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.